Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS

Felicita Andreotti¹, Massimo Massetti¹, Jurrien Ten Berg^{2

3}

Affiliations

¹ Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Department of Cardiology and Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands.
³ Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

Editorial

Felicita Andreotti et al. Eur Heart J. 2022.

. 2022 Aug 1;43(29):2798-2800.

doi: 10.1093/eurheartj/ehac139.

Felicita Andreotti¹, Massimo Massetti¹, Jurrien Ten Berg^{2

3}

¹ Department of Cardiovascular Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
² Department of Cardiology and Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, The Netherlands.
³ Cardiovascular Research Institute Maastricht (CARIM), Maastricht, The Netherlands.

No abstract available

Comment on

Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial.
Collet JP, Van Belle E, Thiele H, Berti S, Lhermusier T, Manigold T, Neumann FJ, Gilard M, Attias D, Beygui F, Cequier A, Alfonso F, Aubry P, Baronnet F, Ederhy S, Kasty ME, Kerneis M, Barthelemy O, Lefèvre T, Leprince P, Redheuil A, Henry P, Portal JJ, Vicaut E, Montalescot G; ATLANTIS Investigators of the ACTION Group. Collet JP, et al. Eur Heart J. 2022 Aug 1;43(29):2783-2797. doi: 10.1093/eurheartj/ehac242. Eur Heart J. 2022. PMID: 35583186 Clinical Trial.